Deuterating Chiral Centers Stabilizes Thalidomide Analogs - C&EN

Advertisement

• ACS
• ACS Publications
• C&EN
• CAS
• Jobs

• Trending:
• Environmental Deregulation
• Artificial Intelligence
• mRNA

Deuterating Chiral Centers Stabilizes Thalidomide Analogs

• Share

Science Briefs Pharmaceuticals Deuterating Chiral Centers Stabilizes Thalidomide Analogs

Method allows researchers to selectively deliver desired enantiomer

by Celia Henry Arnaud

March 16, 2015 1 min read

A version of this story appeared in Volume 93, Issue 11

• Share

Science Briefs

The latest short science news items from C&EN.

Read More

CORRECTION: On April 6, 2015, this story was updated to correct the structure of the deuterated S enantiomer of CC-122.

 

Thalidomide, a racemic drug, is remembered for the birth defects it caused in the 1960s, but thalidomide analogs are now being developed and marketed as anti-inflammatory and anticancer agents. Typically, one enantiomer of a drug compound provides the therapeutic effect. The other enantiomer may be inactive or even detrimental to health. But delivering only the preferred enantiomer can be difficult when the enantiomers rapidly interconvert. By using a method called deuterium-enabled chiral switching, Sheila H. DeWitt of DeuteRx, in Andover, Mass., and coworkers stabilize the desired enantiomers of two thalidomide analogs, CC-11006 and CC-122 (Proc. Natl. Acad. Sci. USA 2015, DOI: 10.1073/pnas.1417832112). Deuterating the chiral centers significantly slows the racemization rate without affecting metabolism or pharmacokinetics of the compounds. The researchers find that in vitro anti-inflammatory and in vivo antitumorigenic properties of CC-122 are caused almost exclusively by the (–)-enantiomer, which is also more active than the racemic mixture. They have not yet determined the absolute configuration of the (–)-enantiomer but believe it is most likely the S form. The company plans to advance the compound as a drug for multiple myeloma, DeWitt says.

• Send the reporter feedback
• Submit a Letter to the Editor for publication

Chemical & Engineering News ISSN 0009-2347 Copyright © 2026 American Chemical Society

Enjoyed the article?

Share Deuterating Chiral Centers Stabilizes Thalidomide Analogs Method allows researchers to selectively deliver desired enantiomer cen.acs.org Advertisement

More in Pharmaceuticals

• Editor's Picks
• Popular

Return to top

2/3

FREE ARTICLES LEFT THIS MONTH

Chemistry matters. Join us to get the news you need. Get More Get More

Close

Must-read Weekly Newsletter

An editor’s selection of the C&EN stories that will continue to spark conversations in the week ahead

Email Address Subscribe

Privacy Policy

Chemistry News That Matters

C&EN empowers those in and around the global chemical enterprise

Upgrade Subscribe to C&EN

Debug leftColumns:

leftColumns exists: no

Share This Article

Close Copy Link Facebook X LinkedIn Bluesky Reddit Wechat Email Print

Share "" via email

Close Send Email to* To send an email to multiple recipients, separate email addresses with a comma, semicolon, or both. Your Name* Your Email Address* Add a Note Optional personal message to include with the shared article. Send Email Sending... Chemical & Engineering News will not share your email address with any other person or company.

Email Sent Successfully

Your email has been sent to

Article: